Plain-English translation of NCT07495072 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Urinary Bladder Neoplasms research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing Blad-Care, a medication designed to protect and restore the bladder lining in patients receiving BCG therapy for early-stage bladder cancer. BCG is a proven cancer treatment, but it often causes uncomfortable bladder symptoms like frequent urination, urgency, pain, and bleeding. The study will compare two different timing schedules for giving the medication to see which approach works best at reducing these side effects.
BCG therapy is very effective at preventing bladder cancer from coming back, but many patients struggle with painful and disruptive bladder symptoms that can make them want to stop treatment. This medication is designed to repair damage to the bladder's natural protective layer, but doctors don't yet know whether starting it early or waiting until after BCG therapy is finished works better.
You likely qualify if…
You likely don't qualify if…
You will receive weekly BCG therapy for six weeks as part of your standard cancer treatment. Depending on which group you're assigned to, you'll either start receiving the protective medication alongside BCG (starting at week 4) or begin it after all six weeks of BCG are complete. The study lasts approximately 8–9 weeks total, and you'll have regular clinic visits to receive treatment and monitor how you're doing.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
South Korea